Picture of Lonza AG logo

LONN — Lonza AG News Story

0.000.00%
ch flag iconLast trade - 00:00
HealthcareBalancedLarge CapHigh Flyer

Brief: Lonza Raises 2026 Margin Outlook After Strong First Half

BRIEF-Lonza Raises 2026 Margin Outlook After Strong First Half

- LONZA GROUP AG LONN.S:

  • LONZA H1 SALES CHF 3,400 MILLION

  • LONZA H1 CORE EBITDA CHF 1,200 MILLION

  • LONZA H1 SALES GROWTH 16%

  • H1 2026 CORE EBITDA CHF 1.20 BILLION, MARGIN 34.8%

  • H1 2026 SALES CHF 3.40 BILLION WITH 16.0% CER SALES GROWTH

  • H1 2026 FREE CASH FLOW CHF 0.40 BILLION

  • ANNOUNCES EXPANSION OF COMMERCIAL-SCALE ADC DRUG PRODUCT CAPACITY IN STEIN, SWITZERLAND

  • UPGRADES 2026 CORE EBITDA MARGIN OUTLOOK TO 33-34%

  • ANNOUNCES EXPANSION OF PAYLOAD-LINKER MANUFACTURING CAPACITY IN VISP, SWITZERLAND

  • FOR 2026, LONZA UPGRADES ITS CORE EBITDA MARGIN OUTLOOK TO 33-34% (PREVIOUSLY: ABOVE 32%) AND CONFIRMS ITS EXPECTATION FOR CER SALES GROWTH OF 11-12%.

  • LONZA EXPECTS PERFORMANCE IN H1 2026 TO SUPPORT ANOTHER STRONG FULL-YEAR RESULT

  • ASSUMING SPOT RATES OF MID-JULY 2026 PREVAIL THROUGH H2, LONZA ANTICIPATES A FX^4 GROWTH HEADWIND OF APPROXIMATELY -2 TO -3% ON SALES IN 2026.

Source text: ID:nEQ2WkppVa

Further company coverage: LONN.S


(Gdansk Newsroom)

((gdansk.newsroom@thomsonreuters.com; +48 587785269;))

Recent news on Lonza AG

See all news